Inventor · disambiguated record
Inger Sandlie
Also filed as: SANDLIE INGER
18 granted patents·30 pending applications·357 citations·filing 1990–2024
94Inventor score
Top patents by PatentIndex Score
48 records- 0195US8748380B2Albumin variantsPLUMRIDGE ANDREW·Filed 2010·Granted Jun 10, 2014·33 cites·20 claims
- 0292US5348876AIgG3 antibodies with shortened hinge region and a complement activation testDYNAL AS·Filed 1990·Granted Sep 20, 1994·187 cites·14 claims
- 0391US10696732B2Albumin variantsALBUMEDIX LTD·Filed 2018·Granted Jun 30, 2020·3 cites·8 claims
- 0489US8822417B2Albumin variantsANDERSEN JAN TERJE·Filed 2012·Granted Sep 2, 2014·27 cites·15 claims
- 0587US8828379B2Disulphide bond-stabilized functional soluble MHC class II heterodimersLOSET GEIR AGE·Filed 2011·Granted Sep 9, 2014·13 cites·11 claims
- 0684US11319383B2Engineered immunoglobulins with altered FcRn bindingUNIV | OSLO·Filed 2017·Granted May 3, 2022·3 cites·7 claims
- 0784US10233228B2Albumin derivatives and variantsPLUMRIDGE ANDREW·Filed 2011·Granted Mar 19, 2019·10 cites·18 claims
- 0881US10208102B2Albumin variants and uses thereofUNIV OSLO·Filed 2014·Granted Feb 19, 2019·6 cites·12 claims
- 0981US9169322B2Modified antibodyBOGEN BJARNE·Filed 2012·Granted Oct 27, 2015·3 cites·29 claims
- 1081US2023303718A1Modified AntibodyNykode Therapeutics ASA·Filed 2023·Application pending·0 cites
- 1178US6294654B1Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop regionSANDLIE INGER·Filed 1996·Granted Sep 25, 2001·63 cites·8 claims
- 1278US2023048561A1Modified AntibodyNykode Therapeutics ASA·Filed 2022·Application pending·0 cites
- 1375US2020385442A1Albumin variantsALBUMEDIX LTD·Filed 2020·Application pending·0 cites
- 1473US10781245B2Albumin variants and uses thereofUNIV OSLO·Filed 2019·Granted Sep 22, 2020·1 cites·8 claims
- 1572US2018105576A1Albumin variantsALBUMEDIX AS·Filed 2017·Application pending·0 cites
- 1672US2024343793A1Antibody variantsTILLOTTS PHARMA AG·Filed 2024·Application pending·0 cites
- 1771US8932603B2Modified antibodyBOGEN BJARNE·Filed 2004·Granted Jan 13, 2015·7 cites·28 claims
- 1870US9598692B2Multivalent phage display systems and methodsLOSET GEIR AGE·Filed 2010·Granted Mar 21, 2017·1 cites·7 claims
- 1970US2018222963A1Albumin variantsALBUMEDIX AS·Filed 2018·Application pending·0 cites
- 2070US2018162925A1Albumin variantsALBUMEDIX AS·Filed 2018·Application pending·0 cites
- 2170US2014234311A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2014·Application pending·0 cites
- 2269US2018105578A1Albumin variantsALBUMEDIX AS·Filed 2017·Application pending·0 cites
- 2369US2018072792A1Albumin variantsALBUMEDIX AS·Filed 2017·Application pending·0 cites
- 2469US2018105577A1Albumin variantsALBUMEDIX AS·Filed 2017·Application pending·0 cites
- 2564US2016075757A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2015·Application pending·0 cites
- 2664US2016075759A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2015·Application pending·0 cites
- 2764US2016009787A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2015·Application pending·0 cites
- 2864US2016075756A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2015·Application pending·0 cites
- 2964US2022348690A1Engineered immunoglobulins with altered fcrn bindingUNIV | OSLO·Filed 2022·Application pending·0 cites
- 3064US2016075760A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2015·Application pending·0 cites
- 3164US2016075763A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2015·Application pending·0 cites
- 3264US2016075762A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2015·Application pending·0 cites
- 3363US2020102368A1Albumin variantsALBUMEDIX LTD·Filed 2019·Application pending·0 cites
- 3462US10640761B2Multivalent phage display systems and methodsUNIV OSLO·Filed 2017·Granted May 5, 2020·0 cites·11 claims
- 3562US2018030155A1Modified AntibodyVACCIBODY AS·Filed 2017·Application pending·0 cites
- 3662US2016075758A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2015·Application pending·0 cites
- 3762US2016075761A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2015·Application pending·0 cites
- 3861US2019113519A1Pharmacokinetic animal modelALBUMEDIX LTD·Filed 2018·Application pending·0 cites
- 3960US11999781B2Antibody variantsTILLOTTS PHARMA AG·Filed 2018·Granted Jun 4, 2024·0 cites·5 claims
- 4058US9056920B2Disulphide bond-stabilized functional soluble MHC class II heterodimersLOSET GEIR AGE·Filed 2014·Granted Jun 16, 2015·0 cites·16 claims
- 4157US9796787B2Modified antibodyVACCIBODY AS·Filed 2015·Granted Oct 24, 2017·0 cites·20 claims
- 4257US2016033523A1Pharmacokinetic animal modelNOVOZYMES BIOPHARMA DK AS·Filed 2014·Application pending·0 cites
- 4354US2014315816A1Albumin variantsNOVOZYMES BIOPHARMA DK AS·Filed 2014·Application pending·0 cites
- 4444US2013225496A1Albumin VariantsPLUMRIDGE ANDREW·Filed 2011·Application pending·0 cites
- 4542US11306318B2Vector constructNEXTERA AS·Filed 2018·Granted Apr 19, 2022·0 cites·34 claims
- 4642US2017107294A1Anti-cd14 antibodies and uses thereofNORDLANDSSYKEHUSET HF·Filed 2014·Application pending·0 cites
- 4739US2004175786A1Anti-cd3 single-chain antibodies having human cmu3 and cmu4 domainsFiled 2001·Application pending·0 cites
- 4835US2019201496A1Blockade of alphafetoprotein (afp) interactions with beta2-microglobulin associated moleculesBRIGHAM & WOMENS HOSPITAL INC·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →